Efficacy and safety of benazepril for advanced chronic renal insufficiency.

BACKGROUND Angiotensin-converting-enzyme inhibitors provide renal protection in patients with mild-to-moderate renal insufficiency (serum creatinine level, 3.0 mg per deciliter or less). We assessed the efficacy and safety of benazepril in patients without diabetes who had advanced renal insufficiency. METHODS We enrolled 422 patients in a randomized, double-blind study. After an eight-week run-in period, 104 patients with serum creatinine levels of 1.5 to 3.0 mg per deciliter (group 1) received 20 mg of benazepril per day, whereas 224 patients with serum creatinine levels of 3.1 to 5.0 mg per deciliter (group 2) were randomly assigned to receive 20 mg of benazepril per day (112 patients) or placebo (112 patients) and then followed for a mean of 3.4 years. All patients received conventional antihypertensive therapy. The primary outcome was the composite of a doubling of the serum creatinine level, end-stage renal disease, or death. Secondary end points included changes in the level of proteinuria and the rate of progression of renal disease. RESULTS Of 102 patients in group 1, 22 (22 percent) reached the primary end point, as compared with 44 of 108 patients given benazepril in group 2 (41 percent) and 65 of 107 patients given placebo in group 2 (60 percent). As compared with placebo, benazepril was associated with a 43 percent reduction in the risk of the primary end point in group 2 (P=0.005). This benefit did not appear to be attributable to blood-pressure control. Benazepril therapy was associated with a 52 percent reduction in the level of proteinuria and a reduction of 23 percent in the rate of decline in renal function. The overall incidence of major adverse events in the benazepril and placebo subgroups of group 2 was similar. CONCLUSIONS Benazepril conferred substantial renal benefits in patients without diabetes who had advanced renal insufficiency. (ClinicalTrials.gov number, NCT00270426.)

[1]  W. Mitch,et al.  A SIMPLE METHOD OF ESTIMATING PROGRESSION OF CHRONIC RENAL FAILURE , 1976, The Lancet.

[2]  F. Locatelli,et al.  Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. , 1996, The New England journal of medicine.

[3]  David Roth,et al.  A simplified equation to predict glomerular filtration rate from serum creatinine , 2000 .

[4]  F. Locatelli,et al.  Effect of the Angiotensin-Converting–Enzyme Inhibitor Benazepril on the Progression of Chronic Renal Insufficiency , 1996 .

[5]  P. Hall Clinical evaluation of renal function. , 1975, Cleveland Clinic quarterly.

[6]  Hai‐yan Wang,et al.  Application of GFR-estimating equations in Chinese patients with chronic kidney disease. , 2005, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[7]  J. Bauer,et al.  Effect of lisinopril monotherapy on renal hemodynamics. , 1988, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[8]  G. Remuzzi,et al.  Effects of dihydropyridine calcium channel blockers, angiotensin-converting enzyme inhibition, and blood pressure control on chronic, nondiabetic nephropathies. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). , 1998, Journal of the American Society of Nephrology : JASN.

[9]  G. Bakris,et al.  Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? , 2000, Archives of internal medicine.

[10]  M. Moser,et al.  Angiotensin-converting enzyme inhibitors, angiotensin II receptor antagonists and calcium channel blocking agents: a review of potential benefits and possible adverse reactions. , 1997, Journal of the American College of Cardiology.

[11]  R. Bain,et al.  The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. , 1993 .

[12]  J. Woo,et al.  Randomized, controlled, parallel-group comparison of ambulatory and clinic blood pressure responses to amlodipine or enalapril during and after treatment in adult chinese patients with hypertension. , 2004, Clinical therapeutics.

[13]  C. Mei,et al.  [Cardiovascular disease in Chinese chronic renal insufficiency patients-epidemiology survey]. , 2005, Zhonghua yi xue za zhi.

[14]  R. Bain,et al.  The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. , 1993, The New England journal of medicine.

[15]  G. Remuzzi,et al.  In chronic nephropathies prolonged ACE inhibition can induce remission: dynamics of time-dependent changes in GFR. Investigators of the GISEN Group. Gruppo Italiano Studi Epidemiologici in Nefrologia. , 1999, Journal of the American Society of Nephrology : JASN.

[16]  G. Remuzzi,et al.  Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. "Gruppo Italiano di Studi Epidemiologici in Nefrologia" (GISEN). , 1998, Kidney international.

[17]  D. Macpherson,et al.  Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors. How much should we worry? , 1998, Archives of internal medicine.

[18]  The Gisen Group Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy , 1997, The Lancet.

[19]  G. Becker,et al.  Angiotensin-converting enzyme inhibition in nondiabetic progressive renal insufficiency: a controlled double-blind trial. , 1996, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[20]  G. Remuzzi,et al.  ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: a post hoc analysis of the REIN trial results. Ramipril Efficacy in Nephropathy. , 2001, Journal of the American Society of Nephrology : JASN.

[21]  Tom Greene,et al.  Calibration and random variation of the serum creatinine assay as critical elements of using equations to estimate glomerular filtration rate. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[22]  T. Greene,et al.  Blood Pressure Control, Proteinuria, and the Progression of Renal Disease , 1995, Annals of Internal Medicine.

[23]  A. Levey,et al.  A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation , 1999, Annals of Internal Medicine.